Background/objectives: Eosinophilic Fasciitis (EF) is a rare connective tissue disorder characterized by skin thickening. Few studies explored its characteristics and factors associated with treatment response.
Methods: PubMed, CENTRAL, Web of Sciences, and Scopus databases were searched in July 2023 to identify all published case reports of EF without restrictions on publication year or language. We extracted patients' demographics, clinical symptoms, laboratory findings, biopsy results and treatment outcomes.
Results: We analyzed 476 published case reports with an aggregate number of 597 patients. The mean age of the patients was 44.52, with a 1:1 male-to-female ratio. Comorbid autoimmune diseases were present in 13.3% of patients. The most common reported skin manifestation was induration (80.7%), with the most commonly affected body part being the legs (77.1%). Only 1.6% of patients had Raynaud's phenomena and 3.1% of patients had Dysphagia. Hypereosinophilia was present in 90.2% and hypergammaglobulinemia was present in 65.9%. Corticosteroids were received by 89.7% of patients. The majority of patients (82.2%) exhibited a clinical response to treatment, but 24.5% of patients who initially responded to treatment relapsed. Patients who received oral corticosteroid monotherapy were significantly more likely to respond to treatment compared to those who received other treatments (56.2% Vs. 39.4%). Patients who had forearm skin involvement (OR = 3.459; 95% CI: 1.334-8.966) had significantly higher odds of clinical response to treatment.
Conclusions: EF is a complex disease with non-specific symptoms. Our study offers comprehensive insights into patient characteristics and treatment outcomes, aiding clinicians in enhancing their approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00296-025-05826-2 | DOI Listing |
Clin Transl Allergy
March 2025
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Background: This study aimed to comprehensively characterize the gut microbiome and identify individual and grouped gut microbes associated with food allergy (FA) using 16S rRNA gene sequencing.
Methods: Fecal samples were collected from children with IgE-mediated FA and from sex- and age-matched controls. The V3-V4 variable regions of the 16S rRNA gene of the gut microbiome were profiled using next-generation sequencing (Illumina, USA).
Ann Med
December 2025
Department of Assisted Reproductive Centre, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, China.
Background: Butyrate may inhibit SARS-CoV-2 replication and affect the development of COVID-19. However, there have been no systematic comprehensive analyses of the role of butyrate metabolism-related genes (BMRGs) in COVID-19.
Methods: We performed differential expression analysis of BMRGs in the brain, liver and pancreas of COVID-19 patients and controls in GSE157852 and GSE151803.
Ren Fail
December 2025
Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Background: IgA nephropathy (IgAN) presents a challenging spectrum of outcomes, often complicated by intrarenal arterial/arteriolar lesions (IALs) in affected individuals. Despite their clinical relevance, existing criteria for classifying and assessing the severity of these lesions remain undefined. This study aimed to establish semi-quantitative assessment criteria for grading IALs and to evaluate their prognostic significance in patients with IgAN.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition with different risk factors, including family history. This study aimed to explore association between a family history of chronic airway disease and features and outcomes of COPD.
Methods: Participants were obtained from the RealDTC study between December 2016 and December 2022.
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!